Home › NDC Lookup › Ingredients › Petrolatum, Cod Liver › 65121-0712-64
🧴image loading
(from DailyMed)

Curefini petrolatum, cod liver 100 mg/mL; 300 mg/mL Ointment, 120 mL — NDC 65121-712-64 (Billing 65121-0712-64)

by Pure Source, LLC · 120 mL in 1 JAR

This is a package of 120 mL of Curefini petrolatum, cod liver 100 mg/mL; 300 mg/mL Ointment from Pure Source, LLC, no longer marketed (first marketed Jan 2013), no longer in the FDA NDC Directory. It is the main listing for this product, which comes in 2 package sizes.

NDC 65121-0712-64
🏷️ FDA NDC (as labeled) 65121-712-64 billing pads the product segment with a zero
This package
Contains120 mL Pack sizes2 compare ↓
Main listing for product 65121-712 · Also comes in: 240 ml 65121-712-65
OTC Discontinued Non-controlled ⚠ Discontinued by firm ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 65121-712-64 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
65121 labeler · 712 product · 64 package
Package marketed since
Feb 7, 2017
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 6512171264 6
FDA record last changed
Jul 24, 2026
⚠️
Excluded from the active FDA NDC Directory. The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Jan 2026. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 65121-712-64
Product NDC 65121-712
11-digit billing NDC 65121071264
RxCUI 1440007
UNII 4T6H12BN9U, BBL281NWFG
Application # M016
SPL Set ID 81059272-b681-4440-8cdf-a8227eadd0c1
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status Discontinued
FDA listing status Discontinued by firm (certified through Jan 2026)
Marketing start 2013-01-17
Route TOPICAL
Dosage form OINTMENT
Substance PETROLATUM; COD LIVER OIL
Quick answers
  • RxCUI (RxNorm): 1440007
Why two NDCs? The FDA registers this code as 65121-712-64 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 65121-0712-64. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

🧪 What is this product?

Curefini is an over-the-counter topical ointment containing cod liver oil and petrolatum. Petrolatum functions as an emollient and occlusive moisturizer commonly used to soften and protect skin. Cod liver oil is typically included in skin care products for its fatty acid content. This is an OTC monograph product, meaning it is marketed under established FDA guidelines for its drug category rather than as an individually approved application.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 240 ml
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
65121-0712-64 You're viewing this Main listing 120 mL in 1 JAR 2017-02-07 — Discontinued by firm
65121-0712-65 65121-712-65 240 mL in 1 JAR 2017-02-07 — Discontinued by firm

You're viewing the smallest of 2 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This package contains 120 mL — 120 ml in 1 jar.
How does this package differ from NDC 65121-0712-65?
Both are Curefini petrolatum, cod liver 100 mg/mL; 300 mg/mL Ointment — the drug itself is identical. This page's package is the 120 mL one, while NDC 65121-0712-65 is the 240 ml package.
What NDC number is used to bill for this package of Curefini petrolatum, cod liver 100 mg/mL; 300 mg/mL Ointment?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Curefini 100 mg/mL; 300 mg/mLthis 65121-0712-64 Pure 120 ml — — Discontinued —
CUREFINI Dermal 300 mg/mL; 100 mg/mL 69981-0704-01 Rev 30 ml — — Discontinued —
CURACID Dermal for cuts and burns 300 mg/mL; 100 mg/mL 69981-0710-04 Rev 120 ml — — Discontinued —
Curefini 300 mg/mL; 100 mg/mL 69981-0712-64 Rev 120 ml — — Discontinued —
Curefini Dermal 300 mg/mL; 100 mg/mL 69981-0754-01 Rev 120 ml — — Discontinued —
Curefini 300 mg/mL; 100 mg/mL 79974-0202-01 Miramar 30 ml — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2013
On the market since
Jan 2013
📍
2026
Currently FDA-listed
13 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

We could not link this NDC to a current FDA Structured Product Label. An inactive-ingredient list is therefore not available from this source.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPure Source, LLC
FDA applicationM016 (OTC MONOGRAPH DRUG)
Labeler code65121
First marketedJan 2013
Product typeHuman Otc Drug
Portfolio31 products on file

More NDCs from Pure Source, LLC labeler code 65121

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 When Using This Product 📄 Keep Out of Reach of Children 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 24 words ▾

Uses: Temporarily protects minor cuts, scrapes and burns. Temporarily protects chapped or cracked skin. Helps protect from drying effects of wind and cold weather.

⏱️ Dosage and Administration 49 words ▾

Directions Apply as needed. Prepare a gauze bandage to apply. Dressing should be placed on a clean and flat surface. Apply ointment with a spatula, covering the entire surface with a thin layer. Place bandage directly on top of affected area. Make sure affected area remains covered by ointment.

⚠️ Warnings 54 words ▾

Warnings: For external use only. When using this product do not get into eyes. If condition worsens or does not improve for seven days, discontinue use and consult a physician. DO NOT USE IF TAMPER EVIDENT SEAL IS BROKEN. Keep out of reach of children. If swallowed, contact physician or poison control center immediately.

🧪 Active Ingredient 12 words ▾

Active Ingredients: Petrolatum 30.00% Cod Liver Oil 10.00 % Purpose: Skin Protectant

🧪 Inactive Ingredients 18 words ▾

Inactive Ingredients: Beeswax, BHT, Chamomilla Recutita (Chamomile) Oil, Helianthus Annuus (Sunflower) Oil, Prunus Amygdalus Dulcis (Sweet Almond) Oil.

🎯 Purpose 3 words ▾

Purpose: Skin Protectant

📄 Do Not Use 9 words ▾

DO NOT USE IF TAMPER EVIDENT SEAL IS BROKEN.

📄 When Using This Product 25 words ▾

When using this product do not get into eyes. If condition worsens or does not improve for seven days, discontinue use and consult a physician.

📄 Keep Out of Reach of Children 15 words ▾

Keep out of reach of children. If swallowed, contact physician or poison control center immediately.

📄 Package Label / Principal Display Panel 5 words ▾

Package Labeling: Curefini 120 Curefini

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for CUREFINI (this brand).

Top reported reactions

Rash45
Pneumonia31
Pruritus31
Cellulitis29
Dyspnoea24
Urinary Tract Infection24
Dizziness23

Age at onset

Neonate5
Infant3
Child9
Adolescent3
Adult57
Elderly59

Reporter sex

435 reports
Male · 55%
Female · 45%

Serious outcomes

Hospitalization260
Death72
Life-threatening49
Disabling8
Reports over time (by year) — tap or hover for the count & year
2021 2022 2024 2026 61 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Over-the-counter (OTC) product No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Otc Monograph Drug". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 240 ml (65121-0712-65). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Pure Source, LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 65121-0711-15 · Pure 65121-0885-23 · Pure →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.